Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multi-Institutional Study of Combination of Luspatercept With Pacritinib (LusPACercept) in Patients With Myelofibrosis Associated Anemia and Thrombocytopenia

NCT07936201 is registered in ClinicalTrials.gov with Case Comprehensive Cancer Center as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07936201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multi-Institutional Study of Combination of Luspatercept With Pacritinib (LusPACercept) in Patients With Myelofibrosis Associated Anemia and Thrombocytopenia
Lead sponsor
Case Comprehensive Cancer Center
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
January 1, 2029
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis

Arms

As registered; 1 arm.

  • LusPACercept combination ExperimentalLuspatercept, Pacritinib

    Luspatercept will be given through subcutaneous injection on Day 1of each cycle at a starting dose of 1.33 milligrams/kilogram and can go up to a maximum dose of 1.75 milligrams/kilogram. Pacritinib will be given twice daily orally at a dose of 200 milligrams. Each cycle lasts 21 days.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Rate of major response for anemia week 24

    The rate of major response for anemia is defined as per 2024 IWG-ELN response criteria for transfusion dependent and non-transfusion dependent partipants with myelofibrosis.

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • Luspatercept 1 Orange Book patentPatent cliff June 30, 2032 (Curated LoE)
    • US 8058229; expires November 8, 2033; assignee Acceleron Pharma (United States)
  • Pacritinib 3 Orange Book patentsPatent cliff March 25, 2030 (Orange Book patent)
    • US 8980873; expires March 25, 2030; assignee CTI BioPharma (United States)
    • US 8153632; expires January 17, 2029; assignee S*BIO Pte Ltd
    • US 9573964; expires May 5, 2028; assignee CTI BioPharma (United States)

Lead sponsor's other trials

Case Comprehensive Cancer Center, most recent start first.

Similar trials

Same condition (Primary Myelofibrosis) and phase, most recent start first.